Hudson Bay Capital Management
ESPR

Hudson Bay Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Hudson Bay Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200,000
Closed -$1.25M – 895
2022
Q4 		$1.25M Buy
+200,000
New +$1.43M 0.01% 669

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management's ESPR Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Esperion Therapeutics (ESPR) stake by 35% in Q1 2026, selling an estimated $20.2K and leaving 11,850 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

Hudson Bay Capital Management first reported a position in ESPR in Q4 2022 and has held it in 3 quarters since. The position peaked at $3.12M in Q4 2022. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Hudson Bay Capital Management held 11,850 shares of Esperion Therapeutics worth $32.5K as of Q1 2026.
  • Hudson Bay Capital Management sold 6,380 Esperion Therapeutics shares in Q1 2026, an estimated $20.2K.
  • Esperion Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1301 holding.
  • Hudson Bay Capital Management first reported a position in Esperion Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • Hudson Bay Capital Management's Esperion Therapeutics position peaked at $3.12M in Q4 2022.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.